Mesoblast gets EU green light for cardiovascular stem cell trial
This article was originally published in Clinica
Australia's Mesoblast has got the go-ahead to start a European Phase IIb trial of its Revascor cardiovascular stem cell therapy. The study, called AMICI, will evaluate the off-the-shelf therapy in 225 heart attack patients in countries including the UK, the Netherlands and Belgium. Mesoblast plans to later expand the trial to include patients in other European countries, as well as the US and Australia.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.